

articles: 323,968,290  
readers: 4,019,034

Will E  
Murdi

**EIN PRESSWIRE**

Reach over 5,000,000  
people with  
one click

[LEARN MORE](#)

[Submit a press release](#) · [See all](#)

**EIN NEWSFEED MAKER**

Get Professional-Quality  
News Delivered to  
Your Website or Blog  
24 Hours a Day

[LEARN MORE](#)

## Got News to Share?

Send 2 FREE Releases



[Menu](#) > [All News Topics](#) > [Healthcare Industry News Topics: By Country | By State](#) ; [Press Releases by Industry Channel](#) > All Healthcare Industry Press Releases

**EIN PRESSWIRE**

## MedGenome announces free access to OncoPeptTOPE™, its proprietary database of neo-antigens and neo-epitopes

*OncoPeptTOPE™ is freely accessible online to DNA / Peptide vaccine researchers*

FOSTER CITY, CA, UNITED STATES, April 29, 2016 /EINPresswire.com/ -- MedGenome recently announced that its proprietary OncoPeptTOPE™ database of neo-antigens and neo-epitopes derived from genetic alterations using TCGA data will be made freely accessible to researchers in the cancer immunotherapy space. The database captures CD4+/CD8+ T-cell neo-epitopes from neo-antigens based on their binding affinity to different HLA types selected based on their expression in cancer cells. The mutated genes are also rank ordered according to their T-cell neo-epitope burden.

The database tool can be accessed online at <http://oncotope.medgenome.com/>. The database has been developed utilizing MedGenome's proprietary pipeline for neo-antigen and neo-epitope identification and prioritization applied against the catalogue of genetic mutations in cancer. The pipeline is also available via the OncoPeptVAC™ service at MedGenome to customers that are focusing on DNA / peptide vaccine development.

MedGenome envisions that access to the OncoPeptTOPE™ database will save a significant amount of analysis time for researchers involved in DNA/Peptide vaccine composition, structure and validations - across discovery, pre-clinical and clinical stages.

